Development of the IL-12/23 antagonist ustekinumab in psoriasis: Past, present, and future perspectives - an update

Annals of the New York Academy of Sciences

Volumn 1263, Issue 1, 2012, Pages 1-12

  Yeilding, Newman ^a   Szapary, Philippe ^a   Brodmerkel, Carrie ^a   Benson, Jacqueline ^a   Plotnick, Michael ^b   Zhou, Honghui ^a   Goyal, Kavitha ^a   Schenkel, Brad ^b   Giles Komar, Jill ^a   Mascelli, Mary Ann ^c   Guzzo, Cynthia ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Janssen Global Services LLC   (United States)

^c Biopharmaceutical Consultant   (United States)

Author keywords

Crohn's disease; Efficacy; Human monoclonal antibody; Interleukin (IL) 12 23; Psoriasis; Psoriatic arthritis; Safety; Ustekinumab

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; USTEKINUMAB;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC GROUP; EUROPE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NAIL PSORIASIS; NONHUMAN; NORTH AMERICA; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SARCOIDOSIS; ULTRAVIOLET A RADIATION;

EID: 84864779984     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06670.x     Document Type: Article

References (14)

1. Yeilding, N., P. Szapary, C. Brodmerkel, et al. 2011. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann. N.Y. Acad. Sci. 1222: 30-39.
2. Kimball, A.B., K.B. Gordon, S. Fakharzadeh, et al. 2012. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br. J. Dermatol. 166: 961-872.
3. Lebwohl, M., C. Leonardi, C.E. Griffiths, et al. 2012. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J. Am. Acad. Dermatol. 66: 731-741.
4. Gordon, K. B., K.A. Papp, R.G. Langley, et al. 2012. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J. Am. Acad. Dermatol. 66: 742-751.
5. Reich, K., K.A. Papp, C.E.M. Griffiths, et al. 2012. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J. Drugs Dermatol. 11: 300-312.
6. Leonardi, C.L., A.B. Kimball, K.A. Papp, et al. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
7. Papp, K.A., R.G. Langley, M. Lebwohl, et al. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
8. Griffiths, C.E., B.E. Strober, P. van de Kerkof, et al. 2010. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362: 118-128.
9. Igarashi, A., T. Kato, M. Kato, et al., THE JAPANESE USTEKINUMAB STUDY GROUP. 2012. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J. Dermatol. 39: 242-252.
10. Nakagawa, H., B. Schenkel, M. Kato, et al. 2012. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled Phase 2/3 trial. J. Dermatol. Mar 13. [Epub ahead of print].
11. Tsai, T.F., J.C. Ho, M. Song, et al., PEARL Investigators. 2011. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J. Dermatol. Sci. 63: 154-163.
12. Tsai, T.F., M. Song, Y-K. Shen, et al. 2012. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate-to-severe psoriasis: Results from the PEARL trial. J. Drugs Dermatol. in press.
13. McInnes, I., A. Kavanaugh, A. Gottlieb, et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Abstract to be presented at: The European League Against Rheumatism (EULAR); June 8, 2012; Berlin, Germany. Oral Presentation OP0158.
14. Sandborn, W.J., C. Gasink, L-L. Gao, et al. A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the CERTIFI Trial. Abstract presented at: Digestive Disease Week (DDW); May 19-22, 2012; San Diego, CA, USA. Abstract 1031129.